Welcome to our dedicated page for Pluri news (Ticker: PLUR), a resource for investors and traders seeking the latest updates and insights on Pluri stock.
Pluri Inc. (Nasdaq: PLUR, TASE: PLUR) is a leading biotechnology company that transforms cells into solutions to promote global wellbeing and sustainability. The company’s core business revolves around developing cell-based products for medical, agricultural, and industrial applications using its proprietary three-dimensional (3D) cell expansion technology. This innovative platform can grow cells in mass quantities with batch-to-batch consistency, making it suitable for applications ranging from regenerative medicine to food technology and beyond.
Pluri's flagship technology leverages placental expanded (PLX) cells that are derived from placental tissue. These cells release biomolecules such as cytokines, chemokines, and growth factors which aid in the healing of damaged tissues by stimulating the body’s natural regenerative mechanisms. The company operates a state-of-the-art manufacturing facility approved by the FDA, EMA, and PMDA, ensuring high standards and regulatory compliance.
In recent developments, Pluri has made significant strides in the agtech industry with the launch of its PluriAgtech business vertical and cell-based coffee product. The company secured a patent from the Israel Patent Office, further establishing its leadership in 3D cell expansion technology. Pluri’s cell-based coffee production method can significantly reduce water usage and farmland requirements, addressing the environmental challenges faced by traditional coffee farming.
Pluri is also advancing in the field of immune cell therapies. The company unveiled a novel method for expanding immune cells and obtained a U.S. patent for this technology, which mimics the natural environment of lymph nodes. This method ensures the integrity and functionality of immune cells, opening new possibilities for treatments of immune disorders and neurodegenerative diseases.
The company actively collaborates with various strategic partners to enhance its technological capabilities and explore new market opportunities. For instance, Pluri partnered with Wilk Technologies to develop cultured human and animal milk products for the elderly, aiming to address the growing demand for medical foods tailored to the nutritional needs of older adults.
Financially, Pluri is well-positioned with robust intellectual property, boasting over 140 active and granted patents. The company continues to expand its market presence, driven by a strong commitment to innovation and sustainability.
To stay updated on Pluri Inc.'s latest news and developments, visit the company’s official website at www.pluri-biotech.com or follow them on LinkedIn and X.
Pluri has entered a €1 million proof of concept (POC) agreement with an international agriculture The collaboration aims to boost global vegetable supply, shorten supply chains, and promote sustainable agriculture. Pluri’s 3D cell expansion technology and the partner's market expertise will work together to minimize environmental impact and enhance food security. This initiative aligns with Pluri's strategy to partner with global companies and generate revenue through innovative projects. The global vegetable farming market, valued at $1.3 trillion, is projected to grow to $1.6 trillion by 2029, driven by a rising global population.
Pluri's subsidiary, Ever After Foods, has secured $10 million in strategic investments from U.S. and EU investors, including Tnuva Group. This funding aims to tackle scalability challenges in cultivated food production. Ever After Foods' innovative platform can produce cultivated meat, fish, and seafood with significant cost-efficiency, reducing production costs by over 90% and increasing protein and lipid yields substantially.
Leveraging Pluri's technology, Ever After Foods aims to expand its global market presence. The technology enables natural production of muscle and fat tissues, ensuring taste and texture akin to conventional meat. The new funding will also broaden Ever After Foods' scope to include cultivated fish, reinforcing its position as a leading technology enabler in the food industry.
Pluri announced that the U.S. National Institute of Allergy and Infectious Diseases (NIAID) has exercised a $1.4 million second-year funding option for a contract to develop PLX-R18, a cell therapy for Acute Radiation Syndrome (H-ARS). The contract, part of a $4.2 million three-year agreement, supports manufacturing, in vitro, and in vivo studies for PLX-R18. The therapy aims to counteract hematopoietic complications from ionizing radiation. Significant survival rate increases in both animal and human studies have been reported. PLX-R18 has also received FDA Orphan Drug Designation.
Pluri (Nasdaq: PLUR) has announced a strategic partnership with Wilk Technologies to create a medical food product derived from human breast milk for the elderly. This innovative product utilizes Pluri's 3D cell-expansion technology in combination with Wilk's cell-cultured milk components. The global elderly nutrition market, valued at $25.2 billion, is projected to reach $39.7 billion within the next decade. This collaboration aims to meet the unique nutritional needs of seniors, enhancing their quality of life while addressing age-related health concerns and chronic illnesses.
Pluri Inc. launched a novel immunotherapy platform for solid tumor cancer treatment utilizing placental MAIT cells, a unique type of immune cells with great potential. Pluri's proprietary technology overcomes challenges in expanding MAIT cells, offering advantages over conventional T cells. The global cancer immunotherapy market is projected to reach $275.11 billion by 2032. Renowned cancer researchers Dr. Prasad S. Adusumilli and Dr. Richard L. Kendall joined Pluri's Scientific Advisory Board to support this groundbreaking platform.
FAQ
What is the current stock price of Pluri (PLUR)?
What is the market cap of Pluri (PLUR)?
What is Pluri Inc. known for?
What are PLX cells?
What recent achievements has Pluri Inc. made?
How does Pluri’s cell-based coffee benefit the environment?
What partnerships has Pluri Inc. entered into recently?
What is Pluri's approach to immune cell therapies?
What markets does Pluri Inc. operate in?
How many patents does Pluri Inc. hold?
Where can I find more information about Pluri Inc.?
What is PLX-R18?
